A long-term study of the most widely used osteoporosis drug has found that many women can discontinue the drug after five years without increasing their fracture risk for as long as five more years.The study on alendronate was led by researchers at the University of California, San Francisco, and findings are published in the December 27, 2006 issue of the “Journal of the American Medical Association.” The research also showed that women at very high risk of painful spine fractures might be better-off continuing treatment.>>> Discuss This Story
